ReviewEuropean urology open science2021
Comparison of
Review in European urology open science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Advancements in Image-Based Analyses for Morphology and Staging of Colon Cancer: A Comprehensive Review.BioMed research international · 2025Pooled it
- Article
- PSMA PET-directed radiotherapy for prostate cancer: From precision planning to future innovations.View (Beijing, China) · 2026Article
- First Clinical Experiences with the Ultra-Fast Time-of-Flight BIOGRAPH One Next-Generation Hybrid PET/MRI System.Diagnostics (Basel, Switzerland) · 2026Article
- Pelvic lymph node management in prostate cancer: a narrative review.Prostate international · 2025Review
- Article
- Evaluation of the tolerability and safety of [BMC cancer · 2024Article
- Primary Staging of Prostate Cancer Patients with [Journal of clinical medicine · 2022Article
- Update of PSMA Theranostics in Prostate Cancer: Current Applications and Future Trends.Journal of clinical medicine · 2022Review
- PET as a Translational Tool in Drug Development for Neuroscience Compounds.Clinical pharmacology and therapeutics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextIn December 2020, the US Food and Drug Administration approved a
objectiveTo compare the diagnostic accuracy of EVIDENCE ACQUISITION: A comprehensive literature search was performed using Embase, PubMed/Medline, Web of Science, Cochrane Library, and Google Scholar up to June 24, 2021 in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Risk of bias was assessed using the QUADAS-2 tool. EVIDENCE SYNTHESIS: The search identified 2632 articles, of which 27 were included. The diagnostic accuracy of
conclusionsPATIENT SUMMARY: The use of radioactively labeled molecules that bind to prostate-specific membrane antigen ( TAKE HOME MESSAGE: After the recent US Food and Drug Administration approval of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.